

## 2021 Michigan Communicable Disease Surveillance and Reporting Changes

---

**Target audience:** Local Health Departments, Physicians, Infection Preventionists, and Laboratories

**Date:** January 2021

**Background:** Each year, the Council of State and Territorial Epidemiologists (CSTE) develops and endorses Position Statements to recommend certain diseases become Nationally Notifiable, that states adopt standardized case definitions, or provide guidance for communication and reporting. This communication is meant to provide notification to our partners of the changes the MDHHS will be making to the official Michigan Reportable Disease List. These changes will be adopted on January 1, 2021.

If you have questions, concerns, or comments about these changes, please contact the MDHHS Communicable Disease Division at 517-335-8165.

### Modifications to Existing Conditions on the Michigan Reportable Disease List:

- **Multisystem Inflammatory Syndrome in Children (MIS-C) assoc. with SARS-CoV-2 infection:** Added condition. CDC has been tracking reports of MIS-C since mid-May 2020. MIS-C is a new syndrome where different body parts can become inflamed, including the heart, lungs, kidney, brain, skin, eyes, or gastrointestinal organs. Many children with MIS-C had a SARS-CoV-2 infection or had an exposure to a suspected or confirmed COVID-19 case. Additional information and the case definition can be found at: <https://www.cdc.gov/mis-c>
- **Carbapenemase Producing-Carbapenem Resistant Enterobacteriaceae (CP-CRE):** Changed 'Enterobacteriaceae' to 'Enterobacterales' (Reportable Disease List by Conditions only)
- **Yersinia enterocolitica (Yersiniosis):** Changed footnote from (4-submit isolates only) to (5) denoting that an isolate is requested to be submitted to the MDHHS Lansing Laboratory

### **Health Care Professional's Guide to Disease Reporting in Michigan Changes**

1. Updated Reportable Disease Lists by Condition (page 6) and by Pathogen (page 11) to reflect 2021 changes described above
2. Updated language for Expedited Partner Therapy (page 8-9)
3. Updated test methods for Carbapenemase-Producing Carbapenem-Resistant Enterobacterales (CP-CRE) (page 12)
4. Removed 'isolates only' from *Yersinia enterocolitica* in the box of suspect isolates that must be forwarded to MDHHS BOL (page 14)